Pacira BioSciences, Inc. (PCRX) intrinsic value & 10-year financials
Pacira BioSciences, Inc. (PCRX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 11.6% a year to $726.4M, with an average return on invested capital of 3.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $36.34
- Market cap
- $1.6B
- Revenue (FY2025)
- $726.4M
- Revenue growth (10-yr CAGR)
- 11.6%
- ROIC (10-yr avg)
- 3.2%
- Free cash flow (FY2025)
- $136.7M
PCRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $726.4M | $7.0M | $0.16 | $136.7M | 2.6% | 0.9% |
| FY2024 | $701.0M | -$99.6M | -$2.15 | $178.8M | -10.5% | -6.0% |
| FY2023 | $675.0M | $42.0M | $0.89 | $139.5M | 13.0% | 4.4% |
| FY2022 | $666.8M | $15.9M | $0.34 | $115.2M | 9.0% | 7.3% |
| FY2021 | $539.0M | $42.0M | $0.92 | $79.9M | 16.7% | 16.6% |
| FY2020 | $426.6M | $145.5M | $3.33 | $39.2M | 10.9% | 10.2% |
| FY2019 | $418.9M | -$11.0M | -$0.27 | $60.4M | 2.5% | 4.1% |
| FY2018 | $332.4M | -$471.0K | -$0.01 | $34.4M | 4.8% | 8.4% |
| FY2017 | $284.3M | -$42.6M | -$1.07 | -$1.5M | -8.8% | -6.1% |
| FY2016 | $270.1M | -$37.9M | -$1.02 | $8.7M | -11.9% | -7.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Pacira BioSciences, Inc. is a consistent compounder, expanding top-line revenue at 11.6% annually over the past decade.
Pacira BioSciences, Inc. has historically struggled to out-earn its cost of capital, averaging just 3.2% ROIC.
Pacira BioSciences, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Pacira BioSciences, Inc. is modeled at -45.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-11.39 per share.